EH3A Stock Overview A pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Amarin Corporation plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Amarin Historical stock prices Current Share Price US$0.41 52 Week High US$1.26 52 Week Low US$0.37 Beta 1.84 1 Month Change -12.39% 3 Month Change -12.77% 1 Year Change -47.10% 3 Year Change -86.01% 5 Year Change -97.88% Change since IPO -80.93%
Recent News & Updates
Amarin Receives National Reimbursement for VAZKEPA in Italy Dec 17
Amarin Corporation plc Appoints Peter Fishman as Chief Financial Officer Dec 13
Nasdaq Grants Amarin Corporation an Additional 180 Calendar Days, or Until May 19, 2025, to Regain Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Nov 23
Third quarter 2024 earnings released: US$0.061 loss per share (vs US$0.047 loss in 3Q 2023) Nov 01 Amarin Corporation plc Announces Executive Changes
Amarin Corporation plc to Report Q3, 2024 Results on Oct 30, 2024 Oct 01 See more updates
Amarin Receives National Reimbursement for VAZKEPA in Italy Dec 17
Amarin Corporation plc Appoints Peter Fishman as Chief Financial Officer Dec 13
Nasdaq Grants Amarin Corporation an Additional 180 Calendar Days, or Until May 19, 2025, to Regain Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Nov 23
Third quarter 2024 earnings released: US$0.061 loss per share (vs US$0.047 loss in 3Q 2023) Nov 01 Amarin Corporation plc Announces Executive Changes
Amarin Corporation plc to Report Q3, 2024 Results on Oct 30, 2024 Oct 01
Now 22% overvalued Sep 30
Now 22% overvalued Aug 28
New major risk - Revenue and earnings growth Aug 11
Now 16% overvalued Aug 06
CEO & President recently bought €94k worth of stock Aug 06
New major risk - Revenue and earnings growth Aug 01
Second quarter 2024 earnings released: EPS: US$0.004 (vs US$0.043 loss in 2Q 2023) Aug 01
Amarin Receives National Reimbursement for Vazkepa® (Icosapent Ethyl) in Portugal Jul 18
Amarin Corporation plc to Report Q2, 2024 Results on Jul 31, 2024 Jul 17 Amarin Corporation plc Announces Executive Changes
Amarin Corporation Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its ADSs Pursuant to Nasdaq Listing Rule 5450(a)(1) May 30
Amarin Corporation plc Receives National Reimbursement for Vazkepa (Icosapent Ethyl) in Greece by Greek Ministry of Health May 29
New minor risk - Profitability May 10
New minor risk - Shareholder dilution May 03
Amarin Corporation plc (NasdaqGM:AMRN) announces an Equity Buyback for $50 million worth of its shares. May 02
Amarin Corporation plc (NasdaqGM:AMRN) announces an Equity Buyback for $50 million worth of its shares. May 01
Amarin Corporation plc to Report Q1, 2024 Results on May 01, 2024 Apr 16
Amarin Corporation plc Announces New Reduce-It® Analyses Show Vascepa®/Vazkepa® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups Apr 08
Amarin Corporation plc, Annual General Meeting, Apr 18, 2024 Mar 05
Full year 2023 earnings released: US$0.14 loss per share (vs US$0.26 loss in FY 2022) Mar 01
Amarin Corporation plc to Report Q4, 2023 Results on Feb 29, 2024 Feb 16
Amarin Regains Compliance with Nasdaq Listing Rule Jan 27
Amarin Corporation plc Provides Revenue Guidance for the Fourth Quarter and Full Year 2023 Jan 10
Now 21% undervalued after recent price drop Nov 06
Amarin Corporation Receives Non-Compliance Notice from Nasdaq Nov 05
Amarin Corporation Receives Non-Compliance Notice from Nasdaq Nov 04
Third quarter 2023 earnings released: US$0.047 loss per share (vs US$0.013 loss in 3Q 2022) Nov 01
Amarin Corporation plc Appoints Jonathan Provoost as New Executive Vice President, Chief Legal & Compliance Officer, Effective November 15, 2023 Nov 01
Amarin Corporation plc to Report Q3, 2023 Results on Nov 01, 2023 Oct 20
President recently bought €286k worth of stock Aug 18
Second quarter 2023 earnings released: US$0.043 loss per share (vs US$0.18 loss in 2Q 2022) Aug 03 Amarin Corporation plc to Report Q2, 2023 Results on Aug 02, 2023
Amarin Corporation plc, Annual General Meeting, Jul 21, 2023 Jun 27
Amarin Corporation plc, Annual General Meeting, Jun 21, 2023 May 27
Amarin Corporation plc Highlights New Data Providing Potential Mechanistic Insight into Vascepa(R)/Vazkepa(R) (Icosapent Ethyl) May 13
First quarter 2023 earnings released: US$0.041 loss per share (vs US$0.079 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$0.26 loss per share (vs US$0.02 profit in FY 2021) Mar 02
Sarissa Capital Releases Investor Presentation to Shareholders of Amarin Corporation Feb 18
Sarissa Capital Management Issues a Statement Regarding Amarin Corporation Feb 17 Sarissa Capital Management Issues a Statement Regarding Amarin Corporation Sarissa Capital Discloses its Views on Amarin Corporation
Sarissa Capital Warns of Amarin’s Expensive Attempts to Switch Votes by Inundating Shareholders with White Proxy Cards Feb 14
Sarissa Capital Issues a Press Release to Shareholders of Amarin Corporation Feb 11
Sarissa Capital Issues a Letter to Shareholders of Amarin Corporation Feb 10
Sarissa Capital Issues a Social Media Post by Alexander J. Denner Relating to Amarin Corporation Feb 09
Sarissa Capital Issues a presentation to Shareholders of Amarin Corporation Feb 08
Sarissa Capital Issues an Investor Presentation to Shareholders of Amarin Corporation Feb 03
Amarin Corporation plc, Annual General Meeting, Feb 28, 2023 Feb 01
Amarin Corporation Provides Information to Shareholders Jan 30
Amarin Corporation plc Announces VAZKEPA (Icosapent Ethyl) Approved By Medsafe In New Zealand Jan 28
Sarissa Capital Calls Out Amarin’s Sham Board Refreshment Jan 19
Sarissa Capital Sends a Requisition Notice to Amarin Corporation Jan 13 Sarissa Capital Sends a Requisition Notice to Amarin Corporation Amarin Corporation plc Provides Revenue Guidance for the the Fourth Quarter and Full Year 2022
High number of new directors Jan 10
Amarin Corporation plc Announces Board Changes Jan 06
Amarin Corporation plc Enters into Settlement Agreement with Health Net, LLC Jan 04 Amarin Corporation plc's Vazkepa (Icosapent Ethyl) Receives Regulatory Approval in Switzerland Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia Nov 16
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors
Amarin Corporation plc Announces New Reduce-It(R) Data Show Vascepa(R)/Vazkepa(R) (Icosapent Ethyl) Reduced Stemi as Well as Other Mi Subtypes Aug 27
Amarin Corporation plc Announces New Research on the Effects of VASCEPA®/VAZKEPA at the European Society of Cardiology Congress Aug 16
Amarin Corporation plc Suspends Revenue Guidance for the Year 2022 Aug 04
Amarin Corporation plc to Report Q2, 2022 Results on Aug 03, 2022 Jul 21
Sarissa Capital Management LP Provides Information to Shareholders of Amarin Corporation plc Jun 18
Amarin Corporation plc Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction Jun 11 Amarin Corporation plc Announces Executive Changes
Sarissa Capital Management LP Engages with Amarin Corporation plc Jun 04
Amarin Corporation plc, Annual General Meeting, Jun 27, 2022 May 25
Amarin Announces Appointment of New Directors and Board Leadership Changes May 20 Amarin Corporation plc Suspends Revenue Guidance for the Full Year 2022
Amarin Corporation plc to Report Q1, 2022 Results on May 04, 2022 Apr 21
Amarin Corporation plc to Report Q1, 2022 Results on May 04, 2022 Apr 20
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 02
Amarin Corporation plc to Report Q4, 2021 Results on Mar 01, 2022 Feb 16
Forecast breakeven date pushed back to 2023 Jan 26 Shareholder Returns EH3A DE Biotechs DE Market 7D 6.8% -2.9% -2.6% 1Y -47.1% -14.7% 6.9%
See full shareholder returns
Return vs Market: EH3A underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is EH3A's price volatile compared to industry and market? EH3A volatility EH3A Average Weekly Movement 13.4% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: EH3A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EH3A's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers.
Show more Amarin Corporation plc Fundamentals Summary How do Amarin's earnings and revenue compare to its market cap? EH3A fundamental statistics Market cap €181.34m Earnings (TTM ) -€37.71m Revenue (TTM ) €230.99m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EH3A income statement (TTM ) Revenue US$241.02m Cost of Revenue US$104.95m Gross Profit US$136.07m Other Expenses US$175.42m Earnings -US$39.35m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.096 Gross Margin 56.46% Net Profit Margin -16.32% Debt/Equity Ratio 0%
How did EH3A perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 15:12 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Amarin Corporation plc is covered by 25 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ritu Baral Canaccord Genuity Chiara Russo Cantor Fitzgerald & Co. Andrew Fein Chardan Capital Markets, LLC
Show 22 more analysts 
